StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 11, 2026, 04:15 PM

Erasca Raises $593.5M in Offering; Q2 Net Loss $44.1M

AI Summary

Erasca, Inc. reported a net loss of $44.1 million for the second quarter of 2026 and $227.5 million for the six months ended June 30, 2026, significantly higher than the prior year due to increased operating expenses, including a $150 million in-process research and development expense. Following the quarter, the company completed an underwritten offering in July 2026, raising $593.5 million in net proceeds. This capital infusion is expected to fund operations for at least one year, despite the accumulated deficit reaching $1.12 billion.

Key Highlights

  • July 2026 underwritten offering raised $593.5M net proceeds.
  • Q2 2026 net loss was $44.1M, up from $33.9M in Q2 2025.
  • Six-month 2026 net loss was $227.5M, up from $64.8M in 2025.
  • Six-month 2026 in-process R&D expense was $150M.
  • Cash, cash equivalents, and restricted cash totaled $42.95M.
  • Total assets increased to $435.1M as of June 30, 2026.
  • Accumulated deficit reached $1.12B by June 30, 2026.